PDCD1 and hepatocellular carcinoma: A Phase II study of TQB2450, an anti-PD-1 IgG1 monoclonal antibody, in combination with anlotinib, is also ongoing in patients with HCC who have failed ICI therapy (FAITH trial; NCT06031480) [53].